Document Detail


Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
MedLine Citation:
PMID:  17565920     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite 0.15% (Alphagan P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan; Pfizer Inc., New York, NY( to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was > or =18 mm Hg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect )10 AM, or approximately 2 h after the morning dose of brimonidine 0.15%(. IOP at trough drug effect (8 AM, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (+/-2.3) mm Hg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mm Hg (26%) at peak drug effect (P<.001) and 3.3 mm Hg (15%) at trough (P<.001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mm Hg (23%) at peak drug effect (P<.001) and 2.0 mm Hg (9%) at trough (P=.002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP.
Authors:
Thomas Mundorf; Robert J Noecker; Melissa Earl
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Advances in therapy     Volume:  24     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2007 Mar-Apr
Date Detail:
Created Date:  2007-06-13     Completed Date:  2007-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  302-9     Citation Subset:  T    
Affiliation:
Private Practice, Charlotte, NC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antihypertensive Agents / administration & dosage,  adverse effects,  therapeutic use*
Drug Therapy, Combination
Female
Glaucoma, Open-Angle / drug therapy*
Humans
Intraocular Pressure / drug effects
Male
Ocular Hypertension / drug therapy*
Prospective Studies
Prostaglandins F, Synthetic / administration & dosage,  adverse effects,  therapeutic use*
Quinoxalines / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Prostaglandins F, Synthetic; 0/Quinoxalines; 130209-82-4/latanoprost; 59803-98-4/brimonidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Celiac plexus block with the long stylet needle technique.
Next Document:  Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in hea...